Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 2;6(10):e2338200.
doi: 10.1001/jamanetworkopen.2023.38200.

Anifrolumab for Adolescent Discoid Lupus Erythematosus

Katharina S Shaw  1   2 , Ahmad Rajeh  3 , Todd Le  4   5 , Philip J Kahn  6 , Vikash S Oza  6   7 , Lisa M Arkin  4   5 , Ruth Ann Vleugels  3   8
Affiliations

Anifrolumab for Adolescent Discoid Lupus Erythematosus

Katharina S Shaw et al. JAMA Netw Open. .
No abstract available

Plain language summary

This case series describes the outcomes among adolescent patients with systemic lupus erythematosus and refractory discoid lupus erythematosus treated with anifrolumab.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Arkin reported serving as a principal investigator on clinical trials for Amgen and Eli Lily on a clinical trial and receiving personal fees from Regeneron and Verrica outside the submitted work. No other disclosures were reported.

Figures

Figure.
Figure.. Clinical Improvement of Recalcitrant Discoid Lupus Erythematosus in Adolescent Patients With Systemic Lupus Erythematosus Treated With Anifrolumab
Representative photographs of 2 adolescent patients demonstrate improvement in discoid lesions on the face (A) and feet (C) after 2 months of treatment (B and D, respectively) with anifrolumab. Line graphs showing Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity (CLASI-A [scores 0-70, where higher scores indicate more severe cutaneous disease activity]) (E) and Damage (CLASI-D [scores 0-56, where higher scores indicate more severe cutaneous damage]) (F) scores for 7 patients before treatment and at month 1, 3, and/or 6 of anifrolumab treatment. Blue circles represent individuals. The orange line indicates mean (SE) CLASI-A (E) and CLASI-D (F) scores calculated before treatment and at months 1 and 6. Patients with missing values at month 6 (n = 2) were excluded from mean calculation. Error bars indicate SEs.
See this image and copyright information in PMC

References

    1. Shaw K, Sanchez-Melendez S, Taylor D, et al. . Assessment of clinical response to anifrolumab in patients with refractory discoid lupus erythematosus. JAMA Dermatol. 2023;159(5):560-563. doi:10.1001/jamadermatol.2023.0175 - DOI - PMC - PubMed
    1. Carter LM, Wigston Z, Laws P, Vital EM. Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers. Br J Dermatol. 2023;189(2):210-218. doi:10.1093/bjd/ljad089 - DOI - PubMed
    1. Vivar KL, Kruse L. The impact of pediatric skin disease on self-esteem. Int J Womens Dermatol. 2017;4(1):27-31. doi:10.1016/j.ijwd.2017.11.002 - DOI - PMC - PubMed
    1. Morand EF, Furie R, Tanaka Y, et al. ; TULIP-2 Trial Investigators . Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211-221. doi:10.1056/NEJMoa1912196 - DOI - PubMed

MeSH terms

Substances